➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Dow
Harvard Business School
Colorcon

Last Updated: November 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SANCTURA XR

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Sanctura Xr

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00863551 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial Completed Allergan Phase 4 2009-04-01 This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory.
NCT00986401 Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects Completed Allergan Phase 1 2009-10-01 The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.
NCT01089751 Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily Completed Allergan Phase 4 2010-03-01 This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.
NCT01178827 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial Completed Allergan Phase 4 2010-08-01 This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.
NCT02386072 A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) Recruiting Astellas Scientific & Medical Affairs, Inc. N/A 2015-01-01 A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form)
NCT04227184 Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence Not yet recruiting National Institute on Aging (NIA) Phase 4 2020-01-22 This is a randomized double-blind crossover trial of trospium and placebo in women with urgency urinary incontinence, with evaluation (history, physical, incontinence evaluation and brain MRI) at baseline, and after each course of therapy. The investigators will evaluate functional brain changes in relation to bladder improvement in order to improve our knowledge of the brain's role in the continence mechanism.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sanctura Xr

Condition Name

Condition Name for Sanctura Xr
Intervention Trials
Overactive Bladder 4
Urinary Bladder Diseases 1
Urgency Urinary Incontinence 1
Pharmacokinetics 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Sanctura Xr
Intervention Trials
Urinary Bladder, Overactive 4
Urinary Bladder Diseases 1
Urinary Incontinence 1
Enuresis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Sanctura Xr

Trials by Country

Trials by Country for Sanctura Xr
Location Trials
United States 39
Canada 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Sanctura Xr
Location Trials
California 3
Arizona 2
Pennsylvania 2
Georgia 1
Idaho 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Sanctura Xr

Clinical Trial Phase

Clinical Trial Phase for Sanctura Xr
Clinical Trial Phase Trials
Phase 4 4
Phase 1 1
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Sanctura Xr
Clinical Trial Phase Trials
Completed 4
Not yet recruiting 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Sanctura Xr

Sponsor Name

Sponsor Name for Sanctura Xr
Sponsor Trials
Allergan 4
Astellas Scientific & Medical Affairs, Inc. 1
Neil M. Resnick 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Sanctura Xr
Sponsor Trials
Industry 5
Other 1
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Mallinckrodt
Express Scripts
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.